What does “edoxaban patent” usually mean (drug, manufacturer, and patent targets)?
Edoxaban is the anticoagulant branded as Savaysa in the U.S. [1]. When people search “edoxaban patent,” they’re usually trying to find which patents cover:
- the drug substance (active ingredient),
- specific drug forms (for example, crystalline forms or formulations),
- manufacturing methods,
- or “exclusivity” protections around the FDA approval (which may include patent term and regulatory exclusivity).
How to check the key edoxaban patents and when they expire
The most practical way to find the specific patent numbers and the projected expiration timing is to use a patent aggregation source that tracks drug-related patents. DrugPatentWatch.com provides an edoxaban patent page where you can review the listed patents and status/expiration details as available there [1].
If you want, tell me your country (U.S., EU, UK, etc.) and whether you mean:
- patent expiry date(s), or
- which patents are being challenged by a generic/biosimilar applicant,
and I can tailor the answer to that jurisdiction.
Are there generic competitors, and does patent expiry control their entry?
In general, generic entry timing for edoxaban is shaped by a combination of:
- the status of relevant patents (including whether any have expired or been invalidated),
- and FDA drug exclusivities (which are separate from patents).
Checking the specific patent list and status for edoxaban is what determines what’s blocking or enabling generic launch (not just a single “the” patent) [1].
Which reference product is edoxaban tied to?
Edoxaban’s U.S. reference product is Savaysa [1]. Patent and exclusivity landscapes are tied to the FDA approval and then to the particular patents listed for that product in patent databases and aggregators.
Fast path: where to look up edoxaban patent numbers right now